Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,900,311
  • Shares Outstanding, K 292,510
  • Annual Sales, $ 191,450 K
  • Annual Income, $ -70,220 K
  • 36-Month Beta 1.98
  • Price/Sales 38.04
  • Price/Cash Flow 0.00
  • Price/Book 60.78

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.03 +33.22%
on 05/30/17
25.22 -4.76%
on 06/27/17
+4.67 (+24.13%)
since 05/26/17
3-Month
18.03 +33.22%
on 05/30/17
25.22 -4.76%
on 06/27/17
+2.74 (+12.88%)
since 03/28/17
52-Week
7.63 +214.81%
on 06/29/16
25.22 -4.76%
on 06/27/17
+16.24 (+208.74%)
since 06/28/16

Most Recent Stories

More News
Top Ranked Momentum Stocks to Buy for June 27th

Top Ranked Momentum Stocks to Buy for June 27th

DE : 123.47 (+1.20%)
EXEL : 24.02 (+1.82%)
LII : 184.50 (+0.13%)
NSC : 120.72 (+1.41%)
Watch for Continued Gains in Shares of Exelixis Inc (EXEL) - June 27, 2017

Shares of Exelixis Inc (NASDAQ:EXEL) traded at a new 52-week high today of $25.22. Approximately 609,000 shares have changed hands today, as compared to an average 30-day volume of 4 million shares.

EXEL : 24.02 (+1.82%)
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment...

AVEO : 2.27 (+8.61%)
JAZZ : 155.18 (+0.21%)
EXEL : 24.02 (+1.82%)
BMY : 55.87 (-0.05%)
Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session

Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day

CARA : 26.95 (+2.01%)
EXEL : 24.02 (+1.82%)
Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics

NEW YORK, NY / ACCESSWIRE / June 27, 2017 / The Dow and S&P 500 eked out modest gains on Monday, despite a poor performance from the technology sector. The Dow Jones Industrial Average gained 0.07 percent...

EXEL : 24.02 (+1.82%)
SGEN : 54.72 (+6.48%)
Biopharma Stock Breakouts With Significant Developments and Market Activity

PALM BEACH, Florida, June 21, 2017 /PRNewswire/ --

CLVS : 93.56 (+4.00%)
IMGN : 7.00 (+7.03%)
EXEL : 24.02 (+1.82%)
EPZM : 15.25 (+6.64%)
MBRX : 3.28 (+65.66%)
Biopharma Stock Breakouts With Significant Developments and Market Activity

As the markets head into the typical summer slowdown period, a few pharma and biotech stocks are putting up impressive performances today such as: Moleculin Biotech Inc. (NASDAQ: MBRX), Exelixis, Inc....

IMGN : 7.00 (+7.03%)
CLVS : 93.56 (+4.00%)
EXEL : 24.02 (+1.82%)
EPZM : 15.25 (+6.64%)
MBRX : 3.28 (+65.66%)
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

BAYRY : 138.9900 (+1.02%)
AVEO : 2.27 (+8.61%)
EXEL : 24.02 (+1.82%)
BMY : 55.87 (-0.05%)
Exelixis's Cabometyx Positive for First-Line Kidney Cancer

Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

EXEL : 24.02 (+1.82%)
RHHBY : 32.7850 (+0.64%)
PFE : 33.75 (-0.06%)
BMY : 55.87 (-0.05%)
Today's Research Reports on Stocks to Watch: Exelixis and Westport Fuel Systems

NEW YORK, NY / ACCESSWIRE / June 20, 2017 / Exelixis had some big news on Monday, announcing that an independent group of reviewers confirmed the company's own conclusion on a phase ii clinical trial...

WPRT : 2.48 (+1.64%)
EXEL : 24.02 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Support & Resistance

2nd Resistance Point 24.82
1st Resistance Point 24.42
Last Price 24.02
1st Support Level 23.35
2nd Support Level 22.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.